FindTrial
Sign In

Risk Assessment, Prediction, and Clinical Strategy Development for Patients with Reproductive Immune Disorders

Risk Assessment, Prediction, and Clinical Strategy Development for Patients with Reproductive Immune Disorders - The Impact of Different Transplantation Strategies on Live Birth Rates in APLS-Positive Patients Undergoing Assisted Reproduction - Risk Assessment, Prediction, and Clinical Strategy Development for Patients with Reproductive Immune Disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119345
Enrollment
Unknown
Registered
2026-02-26
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility Combined with Autoimmune Disorders

Interventions

Frozen embryo transfer:Frozen embryo transfer
Fresh embyro transfer:Fresh embyro transfer

Sponsors

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Women aged 20-40 years with indications for ART who are scheduled for IVF-ET, test positive for aPL, and are capable of independently reading, understanding, and signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Less than 20 years old, older than 40 years old, history of intrauterine adhesions, PGT cycles, polycystic ovary syndrome.

Design outcomes

Primary

MeasureTime frame
Live birth rate;—

Secondary

MeasureTime frame
Miscarriage rate;—

Countries

China

Contacts

Public ContactYuan Zhang

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

zhangyuan_ccrm@126.com+86 25 6830 2222

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026